資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34784
|
| 標題: | Prognostic Significance of DNA Topoisomerase II Alpha (TOP2A) in Cholangiocarcinoma |
| 作者: | Ong, Khaa Hoo
Lai, Hong-Yue
Sun, Ding-Ping
Chen, Tzu-Ju
Huang, Steven Kuan-Hua
Tian, Yu-Feng
Chou, Chia-Lin
Shiue, Yow-Ling
Chan, Ti-Chun
Li, Chien-Feng
Kuo, Yu-Hsuan |
| 貢獻者: | Chi Mei Med Ctr, Dept Surg, Div Gastroenterol & Gen Surg
Chung Hwa Univ Med Technol, Dept Med Technol
Natl Sun Yat Sen Univ, Inst Biomed Sci
China Med Univ, Sch Med, Dept Pharmacol
Chi Mei Med Ctr, Dept Clin Pathol
Chi Mei Med Ctr, Dept Surg, Div Urol
Chang Jung Christian Univ, Coll Hlth Sci, Dept Med Sci Ind
Chi Mei Med Ctr, Dept Surg, Div Colon & Rectal Surg
Natl Sun Yat Sen Univ, Inst Precis Med
Chi Mei Med Ctr, Dept Med Res
Natl Hlth Res Inst, Natl Inst Canc Res
Chi Mei Med Ctr, Trans Lab Precis Med
Chi Mei Med Ctr, Dept Internal Med, Div Hematol & Oncol
Chia Nan Univ, Coll Pharm & Sci |
| 關鍵字: | cholangiocarcinoma
DNA topoisomerase (ATP-hydrolyzing activity) activity
topoisomerase II alpha (TOP2A)
prognostic biomarker |
| 日期: | 2023 |
| 上傳時間: | 2024-12-24 18:00:04 (UTC+8) |
| 出版者: | IMR PRESS |
| 摘要: | Background: Cholangiocarcinoma (CCA) is a malignant tumor with an increasing incidence worldwide. Although radiation therapy has improved the therapeutic efficiency of CCA treatment, differential expression of genes among cholangiocarcinoma subtypes has been revealed through precise sequencing. However, no specific molecular therapeutic targets or biomarkers have been figured out for use in precision medicine, and the exact mechanism by which antitumorigenic effects occur is still unclear. Therefore, it is necessary to conduct further studies on the development and mechanisms associated with CCA. Methods: We examined the clinical data and pathological features of patients with cholangiocarcinomas. We investigated the associations between DNA Topoisomerase II Alpha (TOP2A) expression and patient outcomes, such as metastasis-free survival (MFS) and disease-specific survival (DSS), as well as clinical characteristics and pathological results. Results: TOP2A expression was shown to be upregulated in CCA tissue sections by immunohistochemistry staining and data mining. Moreover, we observed that the TOP2A expression correlated with clinical features, such as the primary tumor stage, histological variants, and patients with hepatitis. Furthermore, high expression of TOP2A was associated with worse survival outcomes in terms of the overall survival (p < 0.0001), disease-specific survival (p < 0.0001), and metastasis-free survival (p < 0.0001) compared with patients in the low TOP2A expression group. This indicates that a high level of TOP2A expression is related to an unfavorable prognosis. Conclusions: Our results show that TOP2A is highly expressed in CCA tissues, and its upregulation is correlated with the primary disease stage and poor prognosis significantly. Consequently, TOP2A is a prognostic biomarker and a novel therapeutic target for the treatment of CCA. |
| 關聯: | Frontiers In Bioscience-Landmark, v.28, n.4, Article 75 |
| 顯示於類別: | [化妝品應用與管理系(所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| 2768-6698-28-4-075.pdf | | 4948Kb | Adobe PDF | 2 | 檢視/開啟 | | index.html | | 0Kb | HTML | 10 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
